

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated November 16, 2021 (the “**Prospectus**”) issued by Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”).*

*This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any Shares or other securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares thereby being offered. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.*

*This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”), or any applicable state securities laws, and may not be offered, sold, pledged or transferred within the United States unless pursuant to an exemption from, or in a transaction that is not subject to, the registration requirements of the U.S. Securities Act. The Offer Shares are being offered and sold outside the United States in offshore transactions in accordance with Regulation S under the U.S. Securities Act. There will be no public offering of the securities of the Company in the United States.*



# Shanghai Bio-heart Biological Technology Co., Ltd.

## 上海百心安生物技術股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code : 2185)**

### **POSTPONEMENT OF THE GLOBAL OFFERING AND REFUND OF APPLICATION MONIES FOR THE HONG KONG PUBLIC OFFERING**

Reference is made to the Prospectus of the Company dated November 16, 2021.

#### **POSTPONEMENT OF THE GLOBAL OFFERING AND THE LISTING**

As stated in the Prospectus, dealing in the H Shares on the Stock Exchange was scheduled to commence at 9:00a.m. on Friday, November 26, 2021.

In light of the prevailing market conditions, the Company, having consulted the Sole Global Coordinator, have decided that the Global Offering will be postponed and will not proceed pursuant to the Prospectus. Accordingly, the International Underwriting Agreement relating to the International Offering will not be entered into and the Hong Kong Underwriting Agreement relating to the Hong Kong Public Offering will not become unconditional.

In the meantime, the Company and the Sole Global Coordinator are carefully assessing the updated timetable in relation to the Global Offering and the Listing. The Company would like to express its gratitude to its prospective investors for their interest in the Company and will update the market as soon as possible.

#### **REFUND OF APPLICATION MONIES**

Application monies in respect of applications made under the **White Form eIPO** service for the Hong Kong Offer Shares (including brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) will be refunded in full without interest. In the case of application monies paid from a single bank account, e-Refund payment instructions will be dispatched to the respective application payment bank accounts on Thursday, November 25, 2021. In the case of application monies paid from multiple bank accounts, refund cheque(s) will be dispatched to the applicants' addresses specified in their **White Form eIPO** application by ordinary post on or before Thursday, November 25, 2021 and at the applicants' own risk.

Applicants who applied for Hong Kong Offer Shares by giving **electronic application instructions** to HKSCC will have all amounts paid on application (including brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) credited to their designated bank accounts or the designated bank accounts of their brokers or custodians without interest on Thursday, November 25, 2021.

Applicants who have instructed their brokers or custodians to give **electronic application instructions** on their behalf can check the amounts of refund monies payable to them with those brokers or custodians.

Applicants who applied as a CCASS Investor Participant can check the amounts of refund monies payable to them via the CCASS Phone System and the CCASS Internet System (under the procedures contained in HKSCC's "An Operating Guide for Investor Participants" in effect from time to time) on Thursday, November 25, 2021. Immediately after the credit of refund monies to the applicants' bank accounts, HKSCC will also make available to them an activity statement showing the amounts of refund monies credited to their designated bank accounts.

All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time.

#### **NO ISSUE OF SHARE CERTIFICATES**

The share certificates for the Offer Shares have not been issued as at the date of this announcement and will not be delivered to any applicants.

By order of the Board  
**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**Philip Li WANG**  
*Chairman*

Hong Kong, Monday, November 22, 2021

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Philip Li WANG as chairman and executive Director, Mr. Yunqing WANG as executive Director, Ms. Li CAI, Mr. Quan ZHOU, Mr. Ji CHEN and Mr. Jie YIN as non-executive Directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. George Chien Cheng LIN as independent non-executive Directors.*